Early Administration of L-carnitine in Hemodialysis Patients

• Status: Completed
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Hemodialysis is a cause of carnitine deficiency. The deficiency of carnitine induces an anemia by an increase fragility of the red blood cells, a muscular fatigue and a cardiac dysfunction. We proposed to evaluate the benefit of an early administration of L-carnitine in hemodialysis patients. The patients should be included in the first month after the start of chronic hemodialysis, randomized to receive L-carnitine or placebo and should be followed-up during one year.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Criteria

Inclusion Criteria:

• Patient with less than 1 month on hemodialysis.

• Treated with rHuEPO.

• Male or female aged of more than 18 years old.

• With contraception treatment for women of procreation age.

• Having received and understand information.

Exclusion Criteria:

• Patients with no need of rHuEPO

• Patients with cancer disease

• Patients with life expectancy under 6 months

• Patients having a proved carnitine deficiency before the start of hemodialysis